Oral Answers to Questions

Rosie Duffield Excerpts

Tuesday 13th January 2026 Commons Chamber

[Wes Streeting]

The hon. Gentleman should absolutely make representations to his local ICB if he has concerns about service reconfigurations. We are investing more in the NHS, but I recognise that there are none the less big challenges for ICBs to face. I am sure that the ICB would be happy to meet him to hear his concerns.

[Rosie Duffield (Canterbury) (Ind)]

3. What discussions he has had with King’s College London on the compliance of the PATHWAYS puberty blocker trial with the Medicines for Human Use (Clinical Trials) Regulations 2004.

[The Minister for Secondary Care (Karin Smyth)]

The PATHWAYS trial has undergone a thorough independent review and has received all the regulatory and ethical approvals. The sponsors of the study, King’s College London and South London and Maudsley NHS foundation trust, are working to ensure that it is conducted in compliance with the relevant regulations.

[Rosie Duffield]

The United States Department of Health and Human Services’ peer-reviewed report found that harms from paediatric medical transition are significant, long term and too often ignored and inadequately tracked, as testified by Keira Bell, who is here in Parliament today. What is the Government’s rationale behind medicalising yet more vulnerable children, given that we have no evidence of any benefit to this approach and, in fact, plenty of evidence of harm?

[Karin Smyth]

As the hon. Lady knows, the Government are acting on the recommendations of the excellent report from Hilary Cass, which I think she would agree is world-leading evidence, and moving the model away from medical intervention towards a more holistic approach to care. The Government will continue to be guided by that evidence, as the whole House will appreciate. The hon. Lady referenced Keira Bell, and I know that my hon. Friend the Member for Birmingham Edgbaston (Preet Kaur Gill) has asked the Secretary of State to meet clinicians and others who disagree with the trial. That meeting is being arranged, and we will continue to work under the guidelines for clinical evidence.